IQity Makes Strong Debut at AAO 2026 with Innovative Surgical Platform

RENO, Nev., Oct. 22, 2026 /CourierPR/ -- IQity, the developer of an integrated diagnostic and surgical platform for ophthalmology, made a strong impression at its first exhibition presence at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting in New Orleans. The company showcased its complete workflow, from preoperative measurement to the operating room, to a US ophthalmologist community over three days.

Luke Clauson, CEO of IQity, noted that the response from surgeons was overwhelmingly positive.

The strongest reaction at the IQity booth was to IQ-SurgiView, the company's heads-up digital surgical visualization system. Surgeons highlighted four key features: the robotic positioning, automated eye identification, the integration of an endoscopic view into the microscope image, and the Floating Eyebox, which follows the surgeon's natural head movement while maintaining full stereopsis, with 16 ms glass-to-glass latency (below the perceptual limit). Visitors repeatedly described the combination as a different way of seeing the surgical field rather than an incremental improvement to existing digital microscopes.

IQ-Flow, a compact, handheld endoscopic cyclophotocoagulation (ECP) system that does not require a capital console, generated the most immediate requests for early access. ECP is an established, reimbursed glaucoma procedure, but adoption has been held back by the cost and footprint of console-based systems and by the learning curve of identifying the target tissue. IQ-Flow is designed to address both, with a handheld form factor and AI-powered machine-vision support intended to help identify the intended target tissue. Many cataract and glaucoma surgeons at the booth said they would want to add ECP to their practice as soon as IQ-Flow becomes available.

IQ-Meter, the integrated diagnostic system designed to combine topography, biometry, aberrometry, OCT, and tear film analysis on a single measurement architecture, was praised for its compact footprint and the breadth of examinations in one device. Surgeons from smaller practices and office-based surgery settings in particular saw it as a fit for the trend toward decentralized, efficient eye care, replacing several standalone devices with a single, fully automated bilateral workup designed to take approximately one minute.

On October 10, four surgeons joined the booth stage for filmed interviews: David Almeida, MD, MBA, PhD (Erie Retina Research, CASEx), Ashley Pickering, MD (North Mississippi Eye Care), Houfar Sekhavat, MD, FRCSC (Hexiris), and Dagny Zhu, MD (Zhu Vision). The series will be published over the coming weeks.

IQity is following up with the surgeons and facilities that registered interest at AAO. A limited number of Center of Excellence sites will be the first to receive the complete workflow at launch, expected in early 2027. Availability of IQ-Meter, IQ-SurgiView, IQ-Flow, and IQ-Universe is expected in early 2027. These technologies have not been cleared by the U.S. Food and Drug Administration (FDA) and are not available for sale in the United States.